Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Test Detects Anti-HIV-1 and Anti-HIV-2 Antibodies

By Labmedica staff writers
Posted on 12 Jun 2008
A diagnostic assay has been developed for the detection of antibodies to human immunodeficiency virus types 1 and/or 2 (anti-HIV-1 and anti-HIV-2).

The new Vitros Anti-HIV 1+2 assays can be run in a fully automated, random access format on the Vitros ECi/ECiQ immunodiagnostic system, with results readily available in less than 50 minutes. More...
The tests can be run at any time, in any order, and with other types of tests. The features of automation and random access increase productivity and efficiency in the laboratory.

Approximately 1,039,000 to 1,185,000 people in the United States are living with HIV/AIDS, with 24-27 % undiagnosed and unaware of their HIV infection. Costs associated with unrecognized or late-recognized HIV infection are growing.

Ortho-Clinical Diagnostics (Rochester, NY, USA) announced that the U.S. Food and Drug Administration (FDA; Rockville, MD) approved its new diagnostic assay for the detection of antibodies to HIV-1 and -2 on the Vitros immunodiagnostic system. The assay was co-developed with Chiron, a business of Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA, USA). The FDA approval and availability to laboratories in the United States, Puerto Rico, and U.S. territories marks the first anti-HIV 1+2 test capable of being run in full random access along swith other tests and providing immediate results upon test completion.


Related Links:
Ortho-Clinical Diagnostics
Chiron
Novartis Vaccines and Diagnostics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.